NeuroDerm
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Ruhrberg Science Bldg 3 Perkeris St, Reh...Phone Number
+972 89462729Website
www.neuroderm.comRevenue
$9.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NeuroDerm
NeuroDerm is an innovative R&D company focused on integrating Pharma and MedTech to develop patient-centric solutions for central nervous system disorders, particularly Parkinson's disease. Their flagship product, ND0612, is a next-generation drug-device combination therapy designed to improve the quality of life for patients experiencing motor fluctuations. The company aims to reduce disease burden through advanced drug delivery systems and digital solutions. NeuroDerm targets patients with Parkinson's disease and their families, striving to enhance healthcare connectivity and well-being.Explore more
NeuroDerm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeuroDerm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NeuroDerm launches new products
NeuroDerm, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once NeuroDerm has new funding data
Congratulate Masked Content for being promoted to Masked Content at NeuroDerm
Check out if NeuroDerm is spiking on competitors!
Click to see if NeuroDerm had a recent Job posting/layoffs
Earning: See what the market has to say on NeuroDerm recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NeuroDerm has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
NeuroDerm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NeuroDerm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NeuroDerm.
NeuroDerm financials insights
Gather financial insights about NeuroDerm, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Unspecified
$5M
2014
Unspecified
$16M
Stock Offering
$45M
2015
Stock Offering
$66.9M
NeuroDerm Tech Stack
A closer look at the technologies used by NeuroDerm
NeuroDerm News & Media
Mitsubishi Tanabe Pharma America Highlights Parkinson's Disease Research at 2025 EAN and ATMRD Congresses
JERSEY CITY, N.J., June 20, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 11th Congress of the European Academy of Neurology (EAN), taking place June 21-24...Mitsubishi Tanabe Pharma America Announces U.S. FDA Acceptance of New Drug Application Resubmission for Investigational ND0612 for the Treatment of Motor Fluctuations in Parkinson's Disease
JERSEY CITY, N.J., May 28, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) resubmission for investigational ND0612, a 24-hours/day, continuous, subcutaneous (SC)...Mitsubishi Tanabe Pharma America Announces Presentations at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD)
JERSEY CITY, N.J., May 7, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD)...Mitsubishi Tanabe Pharma America to Highlight Latest Advances in Neurodegenerative Research at the American Academy of Neurology 2025 Annual Meeting
Presentations will highlight findings from studies evaluating investigational ND0612 in Parkinson's disease and RADICAVA® (edaravone) formulations in ALS JERSEY CITY, N.J., April 3, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced 11 presentations will be...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeuroDerm
Sign Up For FreeTo access detailed company insights
NeuroDerm is an innovative R&D company focused on integrating Pharma and MedTech to develop patient-centric solutions for central nervous system disorders, particularly Parkinson's disease. Their flagship product, ND0612, is a next-generation drug-device combination therapy designed to improve the quality of life for patients experiencing motor flu... Read More
